| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA851: Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer |
|
Medicine details |
|
| Medicine name | pembrolizumab (Keytruda®) |
| Formulation | 25 mg/mL concentrate for solution for infusion |
| Reference number | 3832 |
| Indication | In combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early‑stage triple‑negative breast cancer at high risk of recurrence |
| Company | Merck Sharp & Dohme Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 27/05/2022 |
| NICE guidance | |